Home | Medical Dictionary | Contact Us         
 
 
  • About
    Cedars-Sinai
  • Careers at
    Cedars-Sinai
  • Giving
    & Support
  • Health
    Conditions
  • Healthcare
    Professionals
  • Patients
    & Visitors
  • Programs
    & Services
  • Quality
    Measures
  • Research &
    Education
  • Programs and Services
  • Psychiatry and Behavioral Neurosciences
  • Psychiatry Research
 

Anxiety

Anxiety fills people's lives with overwhelming worry and fear. Unlike the relatively brief anxiety caused by stressful life events, symptoms of anxiety disorders are persistent and can become debilitating if not treated.

The different types of anxiety disorders include:

  • Panic disorder: Panic attacks and avoidance of situations where these might occur
  • Obsessive-compulsive disorder: Obsessive thoughts or compulsive rituals
  • Social phobia: Anxiety in social situations due to fear of humiliation or embarrassment. Social situations may be avoided.
  • Specific phobias: Abnormal fear of heights, snakes, enclosed spaces, etc.
  • Generalized anxiety disorder: Persistent, exhausting worries about usual life events
  • Post-tramautic stress disorder: Re-experience of trauma and avoidance of its reminders
If you have had some of the above symptoms, you may be suffering from an anxiety disorder. Similar to other medical conditions, anxiety can be treated. Cedars-Sinai's Psychiatry Research can help.

Psychiatry Research is currently conducting clinical trials dealing with anxiety disorders and their symptoms. Qualified clinical trial participants will receive study medication, physical exams and laboratory tests at no cost.

Our Anxiety Research Studies:

Investigation of a New Treatment for Generalized Anxiety Disorder: The purpose of this study is to find out if an investigational drug, PD 0332334, can treat generalized anxiety disorder (GAD) and if this drug has any effects on other disorders that may be associated with GAD. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). We are investigating the safety and efficacy of PD 0332334 by comparing it to placebo (an inactive substance) and paroxetine (a drug currently approved for GAD treatment). Participants will be randomly assigned either PD 0332334, paroxetine, or placebo. Participation involves 9 visits over approximately 12 weeks, and those who finish the study may be compensated up to $675.

To find out more about clinical trials on anxiety disorders or to enroll, please contact us at:

Psychiatry Research at the Thalians Mental Health Center
Cedars-Sinai Medical Center
8730 Alden Dr., Room E-123
Los Angeles, CA 90048
Phone: 1-888-CEDARS-3 (233-2773)
Alt Phone: (310) 423-6515
Send Us a Message

 
Cedars-Sinai Logo

© Copyright 2000-2008 Cedars-Sinai Health System.
All rights reserved.
Privacy Policy Terms and Conditions